NCT07189117Recruiting
Cancer and Immune Cell Metabolism in Patients With Hematological Malignancies
Summary
This study investigates how metabolism in cancer and immune cells shapes the bone marrow environment, influences therapy resistance, and affects outcomes in hematological malignancies.
Inclusion criteria
• age \> 18 years, • signed written informed consent • For participants with hematological cancers: diagnosis of MDS, AML, ALL, PMF or post-ET/PV MF
Exclusion criteria
• pregnant or lactating women, • inability to give consent, • active malignant disease (other than MDS, AML, ALL, PMF or post-ET/PV MF in the last 3 - years prior to study inclusion). • For healthy donors: previous or current hematological disease, previous or current other malignant disease,
Contacts
The trial team's contact details are shown on request.
See the official trial record- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Countries
- Switzerland
- Sponsor
- University Hospital, Basel, Switzerland(Other)
- Protocol no.
- 2025-01775;th25Aposotolova
- Conditions
- Hematologic Malignancy
- Interventions
- —
Locations · 1
- Basel, SwitzerlandUniversity Hospital BaselRecruiting at this site
In total, worldwide, the only site listed in the registry is recruiting.
Site status per the ClinicalTrials.gov registry (last update posted: December 23, 2025).
This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.
Other identifiers
- 2025 · NIH grant
See also
Other versions
These results are indicative and do not replace medical advice — discuss them with your doctor.